Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 0.44.

  • Foghorn Therapeutics' Equity Ratio fell 37687.41% to 0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44, marking a year-over-year decrease of 37687.41%. This contributed to the annual value of 0.16 for FY2024, which is 4061.66% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Equity Ratio of 0.44 as of Q3 2025, which was down 37687.41% from 0.34 recorded in Q2 2025.
  • Foghorn Therapeutics' Equity Ratio's 5-year high stood at 0.54 during Q1 2021, with a 5-year trough of 0.44 in Q3 2025.
  • Its 5-year average for Equity Ratio is 0.02, with a median of 0.07 in 2023.
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 14649.48% in 2021, then plummeted by 9769646.8% in 2023.
  • Foghorn Therapeutics' Equity Ratio (Quarter) stood at 0.19 in 2021, then tumbled by 99.85% to 0.0 in 2022, then crashed by 97696.47% to 0.27 in 2023, then surged by 40.62% to 0.16 in 2024, then plummeted by 172.85% to 0.44 in 2025.
  • Its last three reported values are 0.44 in Q3 2025, 0.34 for Q2 2025, and 0.24 during Q1 2025.